Search Results
Results found for "Marie Sklodowska Curie"
- Curve Shifts Don’t Lie, But Your Eyes Might
In This Session, You’ll Gain: ✅ The ability to calculate how many replicates you really need for 95% How Many Replicates Do You Really Need? The second trap is habit. Instead, you’ll calculate exactly how many replicates are needed to detect the differences that matter When Curves Shift Some of the most difficult calls in pharmacology happen when two curves look slightly Real curve shifts? Captured. Artifacts? Dismissed.
- Why Dose-Response Curves Are Pharmacology’s Secret Weapon
From assessing drug potency to predicting effects, these curves aren't just for data—they’re your entry for the humble curve that powers drug discovery. Ready to grasp how a curve can mislead—or enlighten? 👉 Discover why dose-response curves are the backbone of all pharmacology. Unlock "Dose-Response Curves" now
- From One to Many: How a GPCR Curiosity Became a Field-Wide Toolkit
That early curiosity around Family B GPCRs set a 30-year trajectory in motion, culminating in a scalable “The beauty of multiplexing is that you can do many things with one pot of samples.” — Tom Sakmar Enter
- Misread the Curve, Misjudge the Drug: Rethinking Antagonism in GPCR Pharmacology
Why Misreading Antagonism Delays GPCR Drug Discovery If a dose-response curve shifts to the right, you In other words, you can’t diagnose mechanism from curve shape alone . DR curves shift to the right with no loss of maximal effect. He challenges the idea that curve shape alone is diagnostic, pointing out how features like receptor Consider this: Two dose-response curves, side by side.
- Maria’s Travel Blogs: ACSMEDI-EFMC Medicinal Chemistry Frontiers 2025
Our CSO, Maria, has recently traveled to the US to attend the ACSMEDI-EFMC Medicinal Chemistry Frontiers The venue was the UIC Student Center East, and Chicago is a great choice for a city, Maria found it very Wednesday was a key day for Maria, as she got to participate in a panel discussion alongside Dr. Maria alongside the other panelists during Wednesday's panel discussion. Session 8 on Thursday was Maria’s turn to give a talk.
- How to Use Statistical Methods to Strengthen Every GPCR Drug Discovery Decision
Terry's Corner – Curve Shifts Don’t Lie, But Your Eyes Might In early drug discovery, “those curves look Power analysis tells you exactly how many replicates you need for 95% confidence. Bring the curve you’re debating. Ask. Challenge. Get an answer you can defend. Ajay Yekkirala shares the journey from academic pharmacologist to biotech entrepreneur—bridging curiosity
- Genome-wide identification of 216 G protein-coupled receptor (GPCR) genes from the marine water ...
Genome-wide identification of 216 G protein-coupled receptor (GPCR) genes from the marine water flea Here, we identified a total 216 full-length GPCR genes in the marine water flea Diaphanosoma celebensis In this study, these results may provide a better understanding on the evolution of GPCRs, and expand
- Addex and Indivior Extend GABAB Positive Allosteric Modulator Research Collaboration for...
include chronic cough, in addition to the rights to develop certain retained compounds for Charcot-Marie-Tooth
- Are You Guessing or Forecasting? Master GPCR Pharmacologic Models Before It’s Too Late
clarity in GPCR drug discovery Even the strongest GPCR programs stall—not from bad data, but from buried
- Ode to GPCRs
, Gerty Theresa Cori (née Radnitz), and Bernardo Alberto Houssay for their discoveries related to how and Carl Cori on carbohydrate metabolism. Carl Cori – Facts - NobelPrize.org. https://www.nobelprize.org/prizes/medicine/1947/cori-cf/facts/. 4 Gerty Cori - Facts. https://www.nobelprize.org/prizes/medicine/1947/cori-gt/facts/. 5. Cori and Mrs. Cori. Nature 160, 599–599 (1947). https://doi.org/10.1038/160599c0/. 6.
- 📰 GPCR Weekly News, May 6 to 12, 2024
Mark your calendar for September and October 2024. Dr. Maria Waldhoer, JoAnn Trejo, and Anne Marie Quinn. Did you watch Episode #150 of the Dr. GPCR Matchmaking Mark Schmeizl, our Chief Matchmaker, can help you find your perfect match if you want Contact Mark today to get started. Dr. 13 - 17, 2024 | 20th Annual PEGS Boston Summit May 16 - 19, 2024 | ASPET 2024 May 27 - 29, 2024 | SLAS
- Rhodopsin as a Molecular Target to Mitigate Retinitis Pigmentosa
Currently, there is no cure for RP, and the therapeutic options are limited.
- Embark on a GPCR Adventure: Your Weekly Research Expedition! | Oct 21-27, 2024
Dimerization: Unveiling Its Role in Receptor Function and Signaling Sonja Peter , Brian Bender , Chris
- Sosei Heptares Confirms Senior Leadership Changes to Drive the Company Through the Next Stage ...
Chris Cargill appointed as President and Chief Executive Officer • Dr.
- Embark on a GPCR Adventure: Your Weekly Research Expedition! | Oct 21-27, 2024
Dimerization: Unveiling Its Role in Receptor Function and Signaling Sonja Peter , Brian Bender , Chris
- 📰 GPCR Weekly News, October 9 to 15, 2023
success Sosei and PharmEnable extend neurological disease drugs hunt Sosei Heptares’ President & CEO Chris 2024 | Ligand Recognition and Molecular Gating Conference April 5 - 10, 2024 | AACR Annual Meeting May 13 - 17, 2024 | 20th Annual PEGS Boston Summit May 16 - 19, 2024 | ASPET 2024 May 27 - 29, 2024 | SLAS
- GPCR Allostery: Unlock Hidden Mechanisms and Make Smarter Drug Decisions
Your work belongs in the core conversation—not buried in supplementary files.
- 📰 GPCR Weekly News
INV-202, an Oral, Peripherally-acting CB1 Inverse Agonist, in Patients with Diabetic Kidney Disease Chris GEM2023 (14-17 March 2023). 8th and final ERNEST Meeting May 3-7, 2023 in Crete.
- The Five Traps of Ignoring Kinetics
✅ Methods to detect hidden mechanisms—mixtures, dual effects, or time-dependent inhibition—through curve Curves that “look fine” may hide non-equilibrated systems. The fix? Use curve shapes as diagnostics: flattened, biphasic, or lagging responses aren’t noise. Instead of clean monophasic curves, you’ll see biphasic signatures or sequential shifts—first cholinesterase The cure is simple: extend equilibration.
- Decoding Schild Analysis: The Pharmacologist’s Lens on Competitive Antagonism
inhibition follows simple rules—agonist binds, antagonist blocks, and data fit neatly into predictable curves Criteria for genuine competition: Parallel rightward shift of the agonist concentration–response curve Slopes <1 may reveal allosteric modulation , where the antagonist binds at a secondary site. When these same molecules act as antagonists, their curves shift not only in position but also in shape The depression of basal response is accounted for by focusing on curve segments where inhibition behaves
- 📰 GPCR Weekly News, October 16 to 22, 2023
You can find more information about them on the Live Talks page and mark your calendar HERE. Topline Safety and Tolerability Data from Proof-of-Concept Studies Sosei Heptares’ President & CEO Chris 2024 | Ligand Recognition and Molecular Gating Conference April 5 - 10, 2024 | AACR Annual Meeting May 13 - 17, 2024 | 20th Annual PEGS Boston Summit May 16 - 19, 2024 | ASPET 2024 May 27 - 29, 2024 | SLAS
- 📰 GPCR Weekly News, February 13 to 19, 2023
GPCRs, and more Single nucleotide variations encoding missense mutations in G protein-coupled receptors may From the scientist’s view: a conversation with … Chris Tate AI is dreaming up drugs that no one has ever (May 22 - 26, 2023) 2nd LEAPS Meets Life Sciences Conference. (May 14 - 19, 2023) 8th and final ERNEST Meeting in Crete. (May 3 - 7, 2023).
- Extracellular signal-regulated kinases – a potential pathway for GPCR-targeted drug discovery
Sir William Osler Scientists have long sought to discover a “golden bullet” that would cure every disease This emphasis may have caused other signaling pathways to be overlooked due to a need for adequate assay
- Unlocking the Future of Medicine: Advancements in GPCR Research
This week's highlight includes congrats to Omolade Otun, Chris de Graaf, Cherine Bechara, et al. for Be sure to mark your calendars and secure your spot for this extraordinary learning opportunity! Elucidation, and Biological Activity of the Selective TACR2 Antagonist Tumonolide and its Aldehyde from a Marine
- Purpose-Driven Opioid Research: Catherine Demery’s Academic Path
It’s about finding purpose through loss, choosing academia when many peers walk away, and designing science Like many young scientists, she explored different paths and gained industry experience before realizing That alignment between curiosity and urgency set her on the path toward doctoral research. Why Catherine Chose Academia At a time when many early-career scientists debate whether to stay in academia For Catherine, this isn’t just scientific curiosity—it’s urgency.
- 📰 GPCR Weekly News, June 17 to 23, 2024
antifungal potential of phytosterols and triterpenes isolated from Cryptostegia grandiflora against Candida auris
- GPCR Updates: Celebrating Breakthroughs, New Course Launches Soon, and Exclusive Discounts! | Aug 26 - Sep 1, 2024
26th to September 1st, 2024 Industry News GPCR-RAMP Interactome Maps Could Help Drug Developers Find Buried
- From Venice to Virtual Molecules: Alessandro Nicoli’s Unexpected Journey into Computational Chemistry
In this blog post, we dive into his story of scientific curiosity, chance opportunities, and the unlikely ligand data, olfactory GPCRs represent a high-risk, high-reward challenge —perfect for a PhD built on curiosity “Choosing one specific receptor is difficult… they’re unique because they can bind many different molecules
- How Collaboration Sparked a GPCR Imaging Breakthrough in Chemical Biology
What followed — a trip to London, confocal imaging marathons, and a partnership built on trust and curiosity That brief exchange connected two people who had never met but were equally driven by curiosity. For a field that depends on understanding where receptors actually are — and how many are available at Chemical probes may be elegant, but biology isn’t. Tissue is messy. Curiosity also played a central role.
- From Pipettes to Platforms: The Evolution of GPCR Research
Like many, it was a mix of opportunity, timing, and the courage to say yes before everything was figured Mini Timeline: Manual assay years — technical rigor as foundation Technology boom — scaling curiosity


















